Nuclear receptors agonists exert opposing effects on the inflammation dependent survival of breast cancer stem cells

Cell Death and Differentiation

Volumn 19, Issue 7, 2012, Pages 1208-1219

  Papi, A ^a   Guarnieri, T ^a,b,c   Storci, G ^a,c,d   Santini, D ^e   Ceccarelli, C ^e   Taffurelli, M ^a   De Carolis, S ^a,c   Avenia, N ^f   Sanguinetti, A ^f   Sidoni, A ^f   Orlandi, M ^a   Bonafe M ^a,c  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b NATIONAL INSTITUTE OF BIOSTRUCTURES AND BIOSYSTEMS   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

^d Oncology and Laboratory Medicine 'L and A Seragnoli Institute'   (Italy)

^e Departments of Radiology and Hystocytopathology   (Italy)

^f UNIVERSITY OF PERUGIA   (Italy)

Author keywords

cancer stem cells; inflammation; nuclear receptor; PPAR; retinoid

Indexed keywords

6 OH 11 O HYDROXYPHENANTHRENE; CYTOKERATIN 18; ESTROGEN RECEPTOR ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; JAGGED1; NOTCH3 RECEPTOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PHENANTHRENE DERIVATIVE; PIOGLITAZONE; PIRINIXIC ACID; RETINOIC ACID; RETINOIC ACID RECEPTOR; RETINOID X RECEPTOR; TRANSCRIPTION FACTOR SLUG; UNCLASSIFIED DRUG;

ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER STEM CELL; CELL DIFFERENTIATION; CELL STRAIN MCF 7; CELL SURVIVAL; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; MAMMOSPHERE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; STEM CELL EXPANSION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL SURVIVAL; FEMALE; HUMANS; INFLAMMATION; INTERLEUKIN-6; NEOPLASTIC STEM CELLS; NF-KAPPA B; PHENANTHRENES; PPAR GAMMA; PYRIMIDINES; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, RETINOIC ACID; RETINOID X RECEPTORS; THIAZOLIDINEDIONES; TRETINOIN;

EID: 84862118662     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/cdd.2011.207     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T et al. Cancer statistics. A Cancer J Clin 2008; 58: 71-96.
2. Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF. Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100: 3983-3988.
3. Liu S, Wicha MS. Targeting breast cancer stem cells. J Clin Oncol 2011; 28: 4006-4012.
4. Bartkowiak K, Wieczorek M, Buck F, Harder S, Moldenhauer J, Effenberger KE et al. Two-dimensional differential gel electrophoresis of a cell line derived from a breast cancer micrometastasis revealed a stem/progenitor cell protein profile. J Proteome Res 2009; 8: 2004-2014.
5. Korkaya H, Liu S, Wicha MS. Breast cancer stem cells, cytokine networks, and the tumor microenvironment. J Clin Invest 2011; 3: 3804-3809.
6. Sansone P, Storci G, Giovannini C, Pandolfi S, Pianetti S, Taffurelli M et al. p66Shc/Notch-3 interplay controls self-renewal and hypoxia survival in humanstem/progenitor cells of the mammary gland expanded in vitro as mammospheres. Stem Cells 2007; 25: 807-815.
7. Sansone P, Storci G, Tavolari S, Guarnieri T, Giovannini C, Taffurelli M et al. IL6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J Clin Invest 2007; 12: 3988-4002.
8. Zhou J, Zhang H, Gu P, Bai J, Margolick JB, Zhang Y. NF-kappaB pathway inhibitors preferentially inhibit breast cancer stem-like cells. Breast Cancer Res Treat 2008; 111: 419-427.
9. Storci G, Sansone P, Mari S, D'Uva G, Tavolari S, Guarnieri T et al. TNFalpha up-regulates SLUG via the NF-kappaB/HIF1alpha axis, which imparts breast cancer cells with a stem cell-like phenotype. Cell Physiol 2010; 225: 682-691.
10. Bhat-Nakshatri P, Appaiah H, Ballas C, Pick-Franke P, Goulet Jr R, Badve S et al. SLUG/SNAI2 and tumor necrosis factor generate breast cells with CD44 +CD24-phenotype. BMC Cancer 2010; 10: 411-420.
11. Iliopoulos D, Hirsch HA, Struhl K. an epigenetic switch involving in NFkappaB, Lin28, Let-7 micro-RNA and IL6 link to inflammation to cell trasformation. Cell 2009; 139: 693-706.
12. Liu S, Ginestier C, Ou SJ, Clouthier SG, Patel SH, Monville F et al. Breast cancer stem cells are regulated by mesenchymal stem cells through cytokine networks. Cancer Res 2011; 71: 614-624.
13. Konopleva MY, Jordan CT. Leukemia stem cells and microenvironment: biology and therapeutic targeting. J Clin Oncol 2011; 29: 591-599.
14. Rajasekhar V, Studer L, Gerald W, Socci ND, Scher HI. Tumor-initiating stem-like cells in human prostate cancer exhibit increased NFkB signaling. Nat Commun 2011; 12: 162.
15. Chaturvedi MM, Sung B, Yadav VR, Kannappan R, Aggarwal BB. NF-kB addiction and its role in cancer: 'one size does not fit all'. Oncogene 2011; 30: 1615-1630.
16. Tang XH, Gudas LJ. Retinoids, retinoic acid receptors, and cancer. Annu Rev Pathol 2011; 28: 345-364.
17. Ginestier C, Wicinski J, Cervera N, Monville F, Finetti P, Bertucci F et al. Retinoid signaling regulates breast cancer stem cell differentiation. Cell Cycle 2009; 8: 3297-3302.
18. Ho LJ, Lin LC, Hung LF, Wang SJ, Lee CH, Chang DM et al. Retinoic acid blocks proinfiammatoy citokyne-induced matrix metalloproteinase production by downregulating JNK-AP-1 signaling in human chondrocytes. Biochem Pharmacol 2005; 70: 200-208.
19. Hung L-F, Lai J-H, Lin L-C, Wang S-J, Hou T-Y, Chang D-M et al. Retinoic acid inhibits IL-1-indiced iNOS, COX-2 and chemochine production in human chondrocytes. Immunol Investig 2008; 37: 675-693.
20. Germain P, Chambon P, Eichele G, Evans RM, Lazar MA et al. Retinoid X receptors. Pharmacol Rev 2006; 58: 760-772.
21. Papi A, Tatenhorst L, Terwel D, Hermes M, Kummer MP, Orlandi M et al. PPARgamma and RXR ligands act sinergistically as potent antineoplastic agents in vitro and in vivo glioma models. J Neurochem 2009; 109: 1779-1790.
22. Papi A, Rocchi P, Ferreri AM, Orlandi M. RXRgamma and PPARgamma Ligands in Combination to Inhibit Proliferation and Invasiveness in Colon Cancer Cells. Cancer Lett 2010; 297: 65-72.
23. Papi A, Bartolini G, Ammar K, Guerra F, Ferreri AM, Rocchi P et al. Inhibitory effects of retinoic acid and IIF on growth, migration and invasiveness in the U87MG human glioblastoma cell line. Oncol Rep 2007; 18: 1015-1021.
24. Moraes LA, Piqueras L, Bishop-Bailey D. PPAR and inflammation. Pharmacol Ther 2005; 110: 371-385.
25. Bonofiglio D, Cione E, Qi H, Pingitore A, Perri M, Catalano S et al. Combined low doses of PPARgamma and RXR ligands trigger an intrinsic apoptotic pathway in human breast cancer cells. Am J Pathol 2009; 175: 1270-1280.
26. Szanto A, Nagy L. The many faces of PPARgamma: anti-inflammatory by any means? Immunobiology 2008; 213: 789-803.
27. Zhang JZ, Ward KW. WY-14643, a selective PPAR\{alpha\} agonist, induces proinfla. Int J Toxicol 2010; 29: 496-504.
28. Suchanek KM, May FJ, Robinson JA, Lee WJ, Holman NA, Monteith GR et al. Peroxisome Proliferator-Activated Receptor a in the Human Breast Cancer Cell Lines MCF7 and MDA-MB-231. Mol Carcinog 2002; 34: 165-171.
29. Conzen S. Nuclear receptors and breast cancer. Mol Endocrinol 2008; 22: 2215-2228.
30. Vaupel P, Hö ckel M, Mayer A. Detection and characterization of tumor hypoxia using pO2 histography. Antioxid Redox Signal 2007; 9: 1221-1235.
31. Balmer J, Blumhoff R. Gene expression regulation by retinoic acid. J Lipid res 2003; 43: 1773-1809.
32. Mandard S, Muller K, Kersten S. Peroxisome Proliferator actived receptor alpha target genes. Cell Mol Life Sci 2004; 61: 394-416.
33. Dontu G, Abdallah WM, Foley JM, Jackson KW, Clarke MF, Kawamura MJ et al. In vitro propagation and transcriptional profiling of human mammary stem/progenitor cells. Genes Dev 2003; 17: 1253-1270.
34. Studebaker AW, Storci G, Werbeck JL, Sansone P, Sasser AK, Tavolari S et al. Fibroblasts isolated from common sites of breast cancer metastasis enhance cancer cell growth rates and invasiveness in an interleukin-6-dependent manner. Cancer Res 2008; 68: 9087-9095.
35. Dhasarathy A, Kajita M, Wade PA. The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-alpha. Mol Endocrinol 2007; 21: 2907-2918.
36. Tripathi MK, Misra S, Chaudhuri G. Negative regulation of the expressions of cytokeratins 8 and 19 by SLUG repressor protein in human breast cells. Biochem Biophys Res Commun 2005; 329: 508-515.
37. Mazumdar J, Dondeti V, Simon MC. Hypoxia-inducible factors in stem cells and cancer. J Cell Mol Med 2009; 13: 4319-4328.
38. Szanto A, Narkar V, Shen Q, Uray IP, Davies P, Nagy L. Retinoid X receptors: X-ploring their (patho)physiological functions. Cell Death Differ 2004; 11: S126-S143.
39. Yue L, Rasouli N, Ranganathan G, Kern PA, Mazzone T. Divergent effects of peroxisome proliferator-activated receptor gamma agonists and tumor necrosis factor alpha on adipocyte ApoE expression. J Biol Chem 2004; 279: 47626-47632.
40. Chen YC, Pohl G, Wang T, Morin PJ, Risberg B, Kristensen GB et al. Apolipoprotein E is required for cell proliferation and survival in ovarian cancer. Cancer Res 2005; 65: 1331-1338.